Life Sciences News in Poland – April 2026

The regulatory environment in the Life Sciences sector continues to accelerate, with further legislative initiatives and actions by supervisory authorities confirming the high level of variability and complexity of regulations. The past month has brought new draft laws, guidelines, and interpretations that have a real impact on the operational activities and strategic decisions of pharmaceutical companies, medical device manufacturers, healthcare providers, and pharmacies.

In the latest newsletter by DLA Piper Poland, the team of Andrzej Balicki, Ph.D., Jolanta Dąbrowicz, and Urszula Grębowska discusses, among other things:

• planned changes in the area of medicinal products, including the deregulation of advertising to healthcare professionals and the implementation of electronic product information (ePI),
• new EU guidelines and initiatives concerning medical devices, including the reporting of supply interruptions and a pilot program for breakthrough technologies,
• key legislative proposals related to pharmacies, dietary supplements, and e-health, which may significantly impact business models and regulatory obligations of companies.

We invite you to read the newsletter.